Acasti Pharma Stock News

The stock price of Acasti Pharma Inc (NASDAQ: ACST) increased by 52.25% in the previous trading session. This is why it happened.

Are any of these penny stocks on your watchlist right now? The post Best Penny Stocks to Watch as the Market Takes a Bullish Turn appeared first on Penny Stocks to Buy, Picks, News and Information | P

Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT ) shares surged 31.7% to $2.41 after the company announced it was awarded a multiple award blanket purchase agreement by the United States Customs and Border Protection worth up to $90 million over five years. Vertical Aerospace Ltd. (NASDAQ: EVTL ) shares jumped 29.5% to $11.82. Vertical Aerospace recently listed on NYSE following merger with Broadstone Acquisition Corp. Acasti Pharma Inc. (NASDAQ: ACST ) rose 23.9% to $1.3750 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $6 price target. Barnwell Industries, Inc. (NYSE: BRN ) shares jumped 18.9% to $2.9730. Barnwell Industries recently reported Q4 EPS of $0.16 up from $0.08 in the year-ago period. BioRestorative Therapies, Inc. (NASDAQ: BRTX ) gained 18.2% to $5.40 after the company entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO), to conduct BioRestorative''s Phase 2 trial. American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT ) rose 15.6% to $2.15 after gaining around 22% on Tuesday.

After an Oppenheimer upgrade, shares of ACST stock are soaring higher by more than 25%. Why exactly is the investment firm bullish?

Oppenheimer initiated cover Latest Ratings for ACST Date Firm Action From To Dec 2021 Oppenheimer Initiates Coverage On Outperform Dec 2021 Oppenheimer Initiates Coverage Full story available on Benzinga.com

Are any of these penny stocks on your watchlist right now? The post Best Penny Stocks to Watch as the Market Takes a Bullish Turn appeared first on Penny Stocks to Buy, Picks, News and Information | P

Oppenheimer initiated coverage of Acasti Pharma Inc (NASDAQ: ACST) with an Outperform rating and $6 price target. The analyst sees over 400% upside for the stock.

During the last session, Acasti Pharma Inc. (NASDAQ:ACST)s traded shares were 0.53 million, with the beta value of the company hitting 1.42. At the end of the trading day, the stocks price was $1.14, reflecting an intraday gain of 6.54% or $0.07. The 52-week high for the ACST share is $9.76, that puts it down Does Acasti Pharma Inc. (NASDAQ: ACST) Still Look Attractive After A -2.56% Selloff Last Week? Read More »

Acasti Pharma Inc. (NASDAQ:ACST) concluded the trading at $1.29 on Thursday, December 02 with a rise of 1.57% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $1.27 and 5Y monthly beta was reading 1.51 with its price kept floating in the Acasti Pharma Inc. (ACST) Offers An Excellent Investment Opportunity At Current Levels Read More »

Bioavailability of GTX-104 compares favorably with the oral formulation of nimodipine; full PK study expected to report out as planned in H1’22 Bioavailability of GTX-104 compares favorably with the

LAVAL, Québec, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and CEO of Aca

LAVAL, Québec, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan DAlvise, President and CEO of Acasti Pharma, will be participating in the Benzinga All Access event taking place on December 2, 2021.

Acasti Pharma (NASDAQ:ACST) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends. Institutional and Insider Ownership 12.8% of Acasti Pharma shares are held by institutional investors. Comparatively, []

Acasti Pharma Inc. (CVE:ACST)s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$1.92 and last traded at C$1.92, with a volume of 7268 shares traded. The stock had previously closed at C$1.98. The stock has a market capitalization of C$85.92 million and a PE []

Laval, Quebec--(Newsfile Corp. - November 11, 2021) - Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) ("Acasti" or the "Company"), today announced that management will present at the Q4 Investor Summit